|
1
|
Saukkonen K and Hemminki A:
Tissue-specific promoters for cancer gene therapy. Expert Opin Biol
Ther. 4:683–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Evoy D, Hirschowitz EA, Naama HA, Li XK,
Crystal RG, Daly JM and Lieberman MD: In vivo adenoviral-mediated
gene transfer in the treatment of pancreatic cancer. J Surg Res.
69:226–231. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanai F, Lan KH, Shiratori Y, Tanaka T,
Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi
H, et al: In vivo gene therapy for alpha-fetoprotein-producing
hepatocellular carcinoma by adenovirus-mediated transfer of
cytosine deaminase gene. Cancer Res. 57:461–465. 1997.PubMed/NCBI
|
|
4
|
Li Z, Shanmugam N, Katayose D, Huber B,
Srivastava S, Cowan K and Seth P: Enzyme/prodrug gene therapy
approach for breast cancer using a recombinant adenovirus
expressing Escherichia coli cytosine deaminase. Cancer Gene Ther.
4:113–117. 1997.PubMed/NCBI
|
|
5
|
Etienne MC, Chéradame S, Fischel JL,
Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F
and Milano G: Response to fluorouracil therapy in cancer patients:
The role of tumoral dihydropyrimidine dehydrogenase activity. J
Clin Oncol. 13:1663–1670. 1995.PubMed/NCBI
|
|
6
|
Castillo-Rodríguez RA, Arango-Rodríguez
ML, Escobedo L, Hernandez-Baltazar D, Gompel A, Forgez P and
Martínez-Fong D: Suicide HSVtk gene delivery by
neurotensin-polyplex nanoparticles via the bloodstream and GCV
treatment specifically inhibit the growth of human MDA-MB-231
triple negative breast cancer tumors xenografted in athymic Mice.
PLoS One. 9:e971512014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freytag SO, Khil M, Stricker H, Peabody J,
Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D,
Brown S, et al: Phase I study of replication-competent
adenovirus-mediated double suicide gene therapy for the treatment
of locally recurrent prostate cancer. Cancer Res. 62:4968–4976.
2002.PubMed/NCBI
|
|
8
|
Chung-Faye GA, Chen MJ, Green NK, Burton
A, Anderson D, Mautner V, Searle PF and Kerr DJ: In vivo gene
therapy for colon cancer using adenovirus-mediated, transfer of the
fusion gene cytosine deaminase and uracil
phosphoribosyltransferase. Gene Ther. 8:1547–1554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs C, Mitchell EP and Hoff PM:
Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev.
32:491–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jaenisch R and Young R: Stem cells, the
molecular circuitry of pluripotency and nuclear reprogramming.
Cell. 132:567–582. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomson JA, Itskovitz-Eldor J, Shapiro SS,
et al: Embryonic stem cell lines derived from human blastocysts.
Science. 282:1145–1147. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gavrilov S, Papaioannou VE and Landry DW:
Alternative strategies for the derivation of human embryonic stem
cell lines and the role of dead embryos. Curr Stem Cell Res Ther.
4:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khakoo AY, Pati S, Anderson SA, Reid W,
Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, et al:
Human mesenchymal stem cells exert potent antitumorigenic effects
in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao
RC, Ye L and Zhang X: Suppression of tumorigenesis by human
mesenchymal stem cells in a hepatoma Model. Cell Res. 18:500–507.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brignier AC and Gewirtz AM: Embryonic and
adult stem cell therapy. J Allergy Clin Immunol. 125(Suppl 2):
S336–S344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aboody KS, Najbauer J and Danks MK: Stem
and progenitor cell-mediated tumor selective gene therapy. Gene
Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SK, Kim SU, Park IH, Bang JH, Aboody
KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM, et al: Human neural
stem cells target experimental intracranial medulloblastoma and
deliver a therapeutic gene leading to tumor regression. Clin Cancer
Res. 12:5550–5556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aboody KS, Bush RA, Garcia E, Metz MZ,
Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S,
et al: Development of a tumor-selective approach to treat
metastatic cancer. PLoS One. 1:e232006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fodde R: Stem cells and metastatic cancer:
Fatal attraction? PLoS Med. 3:e4822006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muller FJ, Snyder EY and Loring JF: Gene
therapy: can neural stem cells deliver? Nat Rev Neurosci. 7:75–84.
2006. View
Article : Google Scholar
|
|
21
|
Brown AB, Yang W, Schmidt NO, Carroll R,
Leishear KK, Rainov NG, Black PM, Breakefield XO and Aboody KS:
Intravascular delivery of neural stem cell lines to target
intra-cranial and extracranial tumors of neural and non-neural
origin. Hum Gene Ther. 14:1777–1785. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK,
Phi JH, Park IH, Black PM, Carroll RS, Lee J, et al: Targeting rat
brainstem glioma using human neural stem cells and human
mesenchymal stem cells. Clin Cancer Res. 15:4925–4934. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao D, Najbauer J, Garcia E, Metz MZ,
Gutova M, Glackin CA, Kim SU and Aboody KS: Neural stem cell
tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res.
6:1819–1829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yi BR, Hwang KA, Aboody KS, Jeung EB, Kim
SU and Choi KC: Selective antitumor effect of neural stem cells
expressing cytosine deaminase and interferon-beta against ductal
breast cancer cells in cellular and xenograft Models. Stem Cell
Res. 12:36–48. 2014. View Article : Google Scholar
|
|
25
|
Kim SU: Neural stem cell-based gene
therapy for brain tumors. Stem Cell Rev. 7:130–140. 2011.
View Article : Google Scholar
|
|
26
|
Dietrich J, Imitola J and Kesari S:
Mechanisms of disease: The role of stem cells in the biology and
treatment of gliomas. Nat Clin Pract Oncol. 5:393–404. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Auersperg N: Ovarian surface epithelium as
a source of ovarian cancers: Unwarranted speculation or
evidence-based hypothesis? Gynecol Oncol. 130:246–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Egami T, Ohuchida K, Miyoshi K, Mizumoto
K, Onimaru M, Toma H, Sato N, Matsumoto K and Tanaka M:
Chemotherapeutic agents potentiate adenoviral gene therapy for
pancreatic cancer. Cancer Sci. 100:722–729. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fu W, Lan H, Liang S, Gao T and Ren D:
Suicide gene/prodrug therapy using salmonella-mediated delivery of
Escherichia coli purine nucleoside phosphorylase gene and
6-methoxypurine 2′-deoxyriboside in murine mammary carcinoma 4T1
Model. Cancer Sci. 99:1172–1179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim KY, Kim SU, Leung PC, Jeung EB and
Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on
ovarian cancer cells using genetically engineered stem cells:
Tumor-tropic potential and inhibition of ovarian cancer cell
growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Consalvo M, Mullen CA, Modesti A, Musiani
P, Allione A, Cavallo F, Giovarelli M and Forni G:
5-Fluorocytosine-induced eradication of murine adenocarcinomas
engineered to express the cytosine deaminase suicide gene requires
host immune competence and leaves an efficient memory. J Immunol.
154:5302–5312. 1995.PubMed/NCBI
|
|
32
|
Freeman SM, Abboud CN, Whartenby KA,
Packman CH, Koeplin DS, Moolten FL and Abraham GN: The ‘bystander
effect’: Tumor regression when a fraction of the tumor Mass is
genetically Modified. Cancer Res. 53:5274–5283. 1993.PubMed/NCBI
|
|
33
|
Jiang J, Wei D, Sun L, Wang Y, Wu X, Li Y,
Fang Z, Shang H and Wei Z: A preliminary study on the construction
of double suicide gene delivery vectors by mesenchymal stem cells
and the in vitro inhibitory effects on SKOV3 cells. Oncol Rep.
31:781–787. 2014.
|
|
34
|
Dembinski JL, Wilson SM, Spaeth EL,
Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M and Marini FC:
Tumor stroma engraftment of gene-modified mesenchymal stem cells as
anti-tumor therapy against ovarian cancer. Cytotherapy. 15:20–32.
2013. View Article : Google Scholar :
|
|
35
|
Engel JB, Keller G, Schally AV, Nagy A,
Chism DD and Halmos G: Effective treatment of experimental human
endometrial cancers with targeted cytotoxic luteinizing
hormone-releasing hormone analogues AN-152 and AN-207. Fertil
Steril. 83(Suppl 1): S1125–S1133. 2005. View Article : Google Scholar
|
|
36
|
Secord AA, Havrilesky LJ, O’malley DM,
Bae-Jump V, Fleming ND, Broadwater G, Cohn DE and Gehrig PA: A
multicenter evaluation of sequential multimodality therapy and
clinical outcome for the treatment of advanced endometrial cancer.
Gynecol Oncol. 114:442–447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carey MS, Gawlik C, Fung-Kee-Fung M,
Chambers A and Oliver T: Cancer Care Ontario Practice Guidelines
Initiative Gynecology Cancer Disease Site Group: Systematic review
of systemic therapy for advanced or recurrent endometrial cancer.
Gynecol Oncol. 101:158–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fowler JM, Brady WE, Grigsby PW, Cohn DE,
Mannel RS and Rader JS: Sequential chemotherapy and irradiation in
advanced stage endometrial cancer: A Gynecologic Oncology Group
phase I trial of doxorubicin-cisplatin followed by whole abdomen
irradiation. Gynecol Oncol. 112:553–557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bruzzone M, Miglietta L, Franzone P,
Gadducci A and Boccardo F: Combined treatment with chemotherapy and
radiotherapy in high-risk FIGO stage III–IV endometrial cancer
patients. Gynecol Oncol. 93:345–352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim SU, Nakagawa E, Hatori K, Nagai A, Lee
MA and Bang JH: Production of immortalized human neural crest stem
cells. Methods Mol Biol. 198:55–65. 2002.PubMed/NCBI
|
|
41
|
Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB
and Choi KC: Antitumor therapeutic effects of cytosine deaminase
and interferon-β against endometrial cancer cells using genetically
engineered stem cells in vitro. Anticancer Res. 31:2853–2861.
2011.PubMed/NCBI
|
|
42
|
Kim SU: Human neural stem cells
genetically modified for brain repair in neurological disorders.
Neuropathology. 24:159–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jung S, Yi L, Kim J, Jeong D, Oh T, Kim
CH, Kim CJ, Shin J, An S and Lee MS: The role of vimentin as a
methylation biomarker for early diagnosis of cervical cancer. Mol
Cells. 31:405–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Arbyn M, Castellsagué X, de Sanjosé S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Francis SA and Katz ML: The HPV vaccine: A
comparison of focus groups conducted in South Africa and Ohio
Appalachia. Matern Child Health J. 17:1222–1229. 2013. View Article : Google Scholar :
|
|
46
|
Kim HS, Yi BR, Hwang KA, Kim SU and Choi
KC: Anticancer effects of the engineered stem cells transduced with
therapeutic genes via a selective tumor tropism caused by vascular
endothelial growth factor toward HeLa cervical cancer cells. Mol
Cells. 36:347–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tammela T, Enholm B, Alitalo K and
Paavonen K: The biology of vascular endothelial growth factors.
Cardiovasc Res. 65:550–563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ferrara N: Vascular endothelial growth
factor: Basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kang NH, Yi BR, Lim SY, Hwang KA, Baek YS,
Kang KS and Choi KC: Human amniotic membrane-derived epithelial
stem cells display anticancer activity in BALB/c female nude mice
bearing disseminated breast cancer xenografts. Int J Oncol.
40:2022–2028. 2012.PubMed/NCBI
|
|
50
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aboody KS, Najbauer J, Schmidt NO, Yang W,
Wu JK, Zhuge Y, Przylecki W, Carroll R, Black PM and Perides G:
Targeting of melanoma brain metastases using engineered neural
stem/progenitor cells. Neuro Oncol. 8:119–126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rachakatla RS, Marini F, Weiss ML, Tamura
M and Troyer D: Development of human umbilical cord matrix stem
cell-based gene therapy for experimental lung tumors. Cancer Gene
Ther. 14:828–835. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rachakatla RS, Pyle MM, Ayuzawa R, Edwards
SM, Marini FC, Weiss ML, Tamura M and Troyer D: Combination
treatment of human umbilical cord matrix stem cell-based
interferon-beta gene therapy and 5-fluorouracil significantly
reduces growth of metastatic human breast cancer in SCID mouse
lungs. Cancer Invest. 26:662–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
55
|
Larmonier N, Ghiringhelli F, Larmonier CB,
Moutet M, Fromentin A, Baulot E, Solary E, Bonnotte B and Martin F:
Freshly isolated bone marrow cells induce death of various
carcinoma cell lines. Int J Cancer. 107:747–756. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung
EB, Kim SU and Choi KC: Human amniotic fluid-derived stem cells
expressing cytosine deaminase and thymidine kinase inhibits the
growth of breast cancer cells in cellular and xenograft mouse
Models. Cancer Gene Ther. 19:412–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
De Coppi P, Bartsch G Jr, Siddiqui MM, Xu
T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ,
et al: Isolation of amniotic stem cell lines with potential for
therapy. Nat Biotechnol. 25:100–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hajitou A, Trepel M, Lilley CE,
Soghomonyan S, Alauddin MM, Marini FC III, Restel BH, Ozawa MG,
Moya CA, Rangel R, et al: A hybrid vector for ligand-directed tumor
targeting and molecular imaging. Cell. 125:385–398. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Phermthai T, Odglun Y, Julavijitphong S,
Titapant V, Chuenwattana P, Vantanasiri C and Pattanapanyasat K: A
novel method to derive amniotic fluid stem cells for therapeutic
purposes. BMC Cell Biol. 11:792010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tamagawa T, Ishiwata I and Nakamura Y:
Differentiation of human amniotic membrane cells into osteoblasts
in vitro. Hum Cell. 18:191–195. 2005. View Article : Google Scholar
|
|
61
|
Zhang X, Chen X, Wang H and Liu S:
Development of amniotic fluid-derived stem cell. Zhongguo Xiu Fu
Chong Jian Wai Ke Za Zhi. 22:864–868. 2008.In Chinese. PubMed/NCBI
|
|
62
|
Kucerova L, Poturnajova M, Tyciakova S and
Matuskova M: Increased proliferation and chemosensitivity of human
mesenchymal stromal cells expressing fusion yeast cytosine
deaminase. Stem Cell Res. 8:247–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bi WL, Parysek LM, Warnick R and Stambrook
PJ: In vitro evidence that metabolic cooperation is responsible for
the bystander effect observed with HSV tk retroviral gene therapy.
Hum Gene Ther. 4:725–731. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ishii-Morita H, Agbaria R, Mullen CA,
Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG and Blaese RM:
Mechanism of ‘bystander effect’ killing in the herpes simplex
thymidine kinase gene therapy model of cancer treatment. Gene Ther.
4:244–251. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao WH, Cheng JX, Shi PF and Huang JY:
Human umbilical cord mesenchymal stem cells with
adenovirus-mediated interleukin 12 gene transduction inhibits the
growth of ovarian carcinoma cells both in vitro and in vivo. Nan
Fang Yi Ke Da Xue Xue Bao. 31:903–907. 2011.In Chinese. PubMed/NCBI
|
|
66
|
Roufosse CA, Direkze NC, Otto WR and
Wright NA: Circulating mesenchymal stem cells. Int J Biochem Cell
Biol. 36:585–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hu YL, Fu YH, Tabata Y and Gao JQ:
Mesenchymal stem cells: A promising targeted-delivery vehicle in
cancer gene therapy. J Control Release. 147:154–162. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kim SU: Genetically engineered human
neural stem cells for brain repair in neurological diseases. Brain
Dev. 29:193–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yi BR, Hwang KA, Kim YB, Kim SU and Choi
KC: Effects of genetically engineered stem cells expressing
cytosine deaminase and interferon-beta or carboxyl esterase on the
growth of LNCaP prostate cancer cells. Int J Mol Sci.
13:12519–12532. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yi BR, Kim SU, Kim YB, Lee HJ, Cho MH and
Choi KC: Antitumor effects of genetically engineered stem cells
expressing yeast cytosine deaminase in lung cancer brain metastases
via their tumor-tropic properties. Oncol Rep. 27:1823–1828.
2012.PubMed/NCBI
|
|
71
|
Yi BR, Park MA, Lee HR, Kang NH, Choi KJ,
Kim SU and Choi KC: Suppression of the growth of human colorectal
cancer cells by therapeutic stem cells expressing cytosine
deaminase and interferon-β via their tumor-tropic effect in
cellular and xenograft mouse models. Mol Oncol. 7:543–554. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ďuriniková E, Kučerová L and Matúšková M:
Mesenchymal stromal cells retrovirally transduced with
prodrug-converting genes are suitable vehicles for cancer gene
therapy. Acta Virol. 58:1–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Matuskova M, Baranovicova L, Kozovska Z,
Durinikova E, Pastorakova A, Hunakova L, Waczulikova I, Nencka R
and Kucerova L: Intrinsic properties of tumour cells have a key
impact on the bystander effect mediated by genetically engineered
mesenchymal stromal cells. J Gene Med. 14:776–787. 2012. View Article : Google Scholar : PubMed/NCBI
|
